Cervical Castleman's disease associated with benign M-proteinemia: Report of a case
- 19 Downloads
We report the unusual case of a 77-year-old man with cervical Castleman's disease associated with benign M-proteinemia. The patient was found to have an anterior cervical tumor during a follow-up examination after surgery for early gastric cancer, at which time blood biochemistry tests revealed M-proteinemia at the position of β-globulin with a high level of IgG and low levels of IgA and IgM. Serum protein immunoelectrophoresis revealed M-protein consisting of the IgG-k chain, and urine protein immunoelectrophoresis demonstrated Bence Jones protein consisting of the chain. No abnormalities were noted in bone marrow aspiration or bone scintigram. The results of imaging and fine-needle aspiration biopsy of the tumor led to a preoperative diagnosis of cervical malignant lymphoma with suspected M-proteinemia derived from this disease, and resection of the anterior cervical tumor with bilateral neck dissection was performed. Histopathological examination subsequently demonstrated four mixed-type tumors of Castleman's disease. The pathogenesis of Castleman's disease remains unknown; however, we speculate that the complication of benign M-proteinemia in this patient was not incidental, but caused by an underlying immunological abnormality of the B cells.
Key WordsCastleman's disease benign M-proteinemia immunological abnormality of the B cells
Unable to display preview. Download preview PDF.
- 1.Castleman B, Inverson L, Menendez VP (1956) Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 9:822–830Google Scholar
- 2.Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683Google Scholar
- 3.Gaba AR, Stein RS, Sweet DL, Variakojis D (1978) Multicentric giant lymph node hyperplasia. Am J Clin Pathol 69:86–90Google Scholar
- 4.Fizzera G, Peterson BA, Bayrd ED, Goldman A (1985) A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: Clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3:1202–1216Google Scholar
- 5.Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74:1360–1367Google Scholar
- 6.Beck JT, Hsu S-M, Wijdens J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B (1994) Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330:602–605Google Scholar
- 7.Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF/IL-6 for human multiple myeloma. Nature 332:83–85Google Scholar
- 8.Nakanishi T, Sobue I, Toyokura Y, Nishitani H, Kuroiwa Y, Satoyoshi E, Tsubaki T, Igata A, Ozaki Y (1984) The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 34:712–720Google Scholar
- 9.Mandler RN, Kerrigan DP, Smart J, Kuis W, Villinger P, Lotz M (1992) Castleman's disease in POEMS syndrome with elevated inter-leukin-6. Cancer 69:2697–2703Google Scholar